The clean safety profile supports advancing nintedanib DPI into Phase 2, reducing clinical risk for this asset. Monitor Phase 2 enrollment updates and future efficacy readouts (FVC decline) as key catalysts. The conference call at 4:30 p.m. ET today may provide additional detail on development timelines.
Price Chart
Executive Summary
MannKind announced positive topline safety and tolerability results from its Phase 1b INFLO-1 study of nintedanib DPI (MNKD-201) in idiopathic pulmonary fibrosis (IPF). The study met its primary endpoint with no serious adverse events, no gastrointestinal side effects, no bronchospasm, and no treatment discontinuations, while cough events were mild and transient. The global Phase 2 INFLO-2 trial is now actively enrolling, supporting continued pipeline development in a large unmet need market.
Key Facts
- Phase 1b INFLO-1 met primary safety/tolerability endpoint in 27 IPF patients across 10 U.S. sites
- No serious adverse events, no drug-related GI side effects, no bronchospasm, no discontinuations or dose reductions
- Cough was predominantly mild/transient with no cough-related discontinuations; ~450 inhalations administered in IPF patients
- Global Phase 2 INFLO-2 actively enrolling ~210 patients across ~85 sites worldwide
- MannKind has two FDA-approved DPI products using the Technosphere platform, supporting formulation expertise
Financial Impact
Positive Phase 1b data de-risks MNKD-201 pipeline; Phase 2 enrollment underway; no financial figures disclosed
Risk Factors
- Phase 2 may not replicate safety profile or demonstrate efficacy on FVC endpoints
- Competition from oral nintedanib (Ofev) and other IPF therapies may limit commercial potential
- Regulatory pathway for inhaled nintedanib remains uncertain until larger trials complete
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3335054 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 29, 2026 9w ago | Press Release | $3.85 $4.09 | ▲ +6.23% | ▲ +1.21% | $3.72 (−3.38%) |
Jul 24, 2026 9w ago | 8-K | $3.95 $4.07 | ▲ +3.04% | ▼ −0.26% | $3.72 (−5.82%) |
Jul 18, 2026 10w ago | Insider Cluster | $3.98 $3.90 | ▼ −2.01% | ▼ −6.13% | $3.72 (−6.53%) |
Jun 3, 2026 17w ago | Press Release | $3.36 $4.52 | ▲ +34.52% | ▲ +35.52% | $3.72 (+10.71%) |
Jun 2, 2026 17w ago | 8-K | $3.43 $4.05 | ▲ +18.08% | ▲ +19.64% | $3.72 (+8.45%) |
May 29, 2026 18w ago | Press Release | $3.77 $4.24 | ▲ +12.47% | ▲ +14.26% | $3.72 (−1.33%) |
May 29, 2026 18w ago | Press Release | $3.77 $4.24 | ▲ +12.47% | ▲ +14.26% | $3.72 (−1.33%) |
May 28, 2026 18w ago | 8-K | $3.64 $4.14 | ▲ +13.74% | ▲ +16.88% | $3.72 (+2.20%) |
May 27, 2026 18w ago | Press Release | $3.55 $3.93 | ▲ +10.70% | ▲ +12.61% | $3.72 (+4.79%) |
May 12, 2026 20w ago | Insider Cluster | $3.28 $3.63 | ▲ +10.67% | ▲ +12.40% | $3.72 (+13.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access